Enhance Immuno-Oncology Research With Knock-Out Cell Lines

This content is brought to you by Abcam, a Danaher Operating Company.

Exploring the correlation between genotype and phenotype is a complex task that relies on multiple methods and techniques. However, integrating robust tools, such as knock-out (KO) cell lines and high-throughput assays, can reveal the impact of gene disruption within immuno-oncology pathways, supporting the identification of future pharmaceutical targets.

In this application note, a human PD-L1 KO cell line (ab267054) is employed in conjunction with the human cytokine FirePlex®-384 assay (ab234897) and the SimpleStep® ELISA kit (ab277712) to illustrate the role of PD-L1 in modulating T cell responses. Gain insight into the effectiveness of highly validated KO cell lines for studying immuno-oncology pathways.